150321-05-4

Upstream product

• 590-28-3 potassium cyanate 
• 150301-88-5 N-<4-<2-(5-methyl-2-phenyloxazol-4-yl)ethoxy>benzyl>hydroxylamine 
• 1118-02-1 trimethylsilyl isocyanate 
• 103788-59-6 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzaldehyde 
• 141820-05-5 4-<2-(5-methyl-2-phenyloxazol-4-yl)ethoxy>benzaldehyde oxime 

Relevant academic research and scientific papers

Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5- lipoxygenase

Azole phenoxy hydroxyureas are a new class of 5-lipoxygenase (5-LO) inhibitors. Structure-activity relationship studies have demonstrated that electronegative substituents on the 2-phenyl portion of the oxazole tail increased the ex vivo potency of these

Hypoglycemic hydroxyurea derivatives

There are disclosed preparative processes and hypoglycemic compounds of the formula STR1 wherein R is hydrogen or C1 to C3 alkyl; R1 and R2 are taken together and are carbonyl; or R1 and R2 are taken separately, wherein R1 is hydrogen or R4 and R2 is--COR5 and COOR5 ; R3, R4 and R5 are each independently C1 to C9 alkyl, C3 to C7 cycloalkyl, phenyl, naphthyl, furyl, benzofuryl or thienyl or one of said groups mono- or disubstituted with C1 to C3 alkyl, C1 to C3 alkoxy, C1 to C3 alkoxy-carbonyl, trifluoromethyl, fluoro or chloro; and n is 0 or 1; or pharmaceutically acceptable cationic salts thereof.